RadBone: bone toxicity following pelvic radiotherapy - a prospective randomised controlled feasibility study evaluating a musculoskeletal health package in women with gynaecological cancers undergoing pelvic radiotherapy.
clinical trials
gynaecological oncology
musculoskeletal disorders
radiotherapy
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
14 06 2022
14 06 2022
Historique:
entrez:
14
6
2022
pubmed:
15
6
2022
medline:
18
6
2022
Statut:
epublish
Résumé
Patients receiving radiotherapy are at risk of developing radiotherapy-related insufficiency fractures, which are associated with increased morbidity and pose a significant burden to patients' quality of life and to the health system. Therefore, effective preventive techniques are urgently required. The RadBone randomised controlled trial (RCT) aims to determine the feasibility and acceptability of a musculoskeletal health package (MHP) intervention in women undergoing pelvic radiotherapy for gynaecological malignancies and to preliminary explore clinical effectiveness of the intervention. The RadBone RCT will evaluate the addition to standard care of an MHP consisting of a physical assessment of the musculoskeletal health, a 3-month prehabilitation personalised exercise package, as well as an evaluation of the fracture risk and if required the prescription of appropriate bone treatment including calcium, vitamin D and-for high-risk individuals-bisphosphonates. Forty participants will be randomised in each group (MHP or observation) and will be followed for 18 months. The primary outcome of this RCT will be feasibility, including the eligibility, screening and recruitment rate, intervention fidelity and attrition rates; acceptability and health economics. Clinical effectiveness and bone turnover markers will be evaluated as secondary outcomes. This study has been approved by the Greater Manchester East Research Ethics Committee (Reference: 20/NW/0410, November 2020). The results will be published in peer-reviewed journals, will be presented in national and international conferences and will be communicated to relevant stakeholders. Moreover, a plain English report will be shared with the study participants, patients' organisations and media. NCT04555317.
Identifiants
pubmed: 35701060
pii: bmjopen-2021-056600
doi: 10.1136/bmjopen-2021-056600
pmc: PMC9198686
doi:
Substances chimiques
Diphosphonates
0
Banques de données
ClinicalTrials.gov
['NCT04555317']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e056600Subventions
Organisme : Medical Research Council
ID : MR/M008959/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T024887/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Proteome Res. 2019 Sep 6;18(9):3369-3382
pubmed: 31408348
Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):840-847
pubmed: 27663759
Lancet. 1999 Mar 13;353(9156):878-82
pubmed: 10093980
Pilot Feasibility Stud. 2018 Jun 05;4:110
pubmed: 29992040
Bone. 2014 Oct;67:33-40
pubmed: 24998454
Eur J Surg Oncol. 2021 Mar;47(3 Pt A):524-532
pubmed: 32439265
Clin Transl Oncol. 2015 Jun;17(6):454-61
pubmed: 25425023
Endocr Rev. 2019 Jun 1;40(3):711-767
pubmed: 30476004
Clin Oncol (R Coll Radiol). 2015 Nov;27(11):668-78
pubmed: 26276560
Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):475-484
pubmed: 31580930
Bone. 2010 Jan;46(1):101-11
pubmed: 19747571
EBioMedicine. 2015 Jun 19;2(8):841-50
pubmed: 26425690
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1183-8
pubmed: 17919836
BMC Med Res Methodol. 2013 Aug 20;13:104
pubmed: 23961782
Joint Bone Spine. 2003 Aug;70(4):287-9
pubmed: 12951312
Cochrane Database Syst Rev. 2018 Apr 23;4:CD010604
pubmed: 29683475